(Deudextromethorphan hydrobromide + quinidine sulfate) is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase III drugs for Dementia Associated With Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Deudextromethorphan hydrobromide + quinidine sulfate)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Deudextromethorphan hydrobromide + quinidine sulfate) overview
AVP-786 is under development for the treatment of agitation associated with dementia of the Alzheimer's type. It is a next-generation Nuedexta. The drug candidate is administered as capsule through oral route. It consists of a combination of deuterium modified dextromethorphan hydrobromide and ultra-low dose quinidine sulfate. It is an NMDA receptor antagonist and acts as a non-competitive channel blocker. The drug candidate is developed using DCE Platform (Deuterated Chemical Entity Platform) technology that produces several deuterium-modified dextromethorphan compounds. It was under development for schizophrenia, intermittent explosive disorder, levodopa-induced dyskinesia in Parkinson's disease, traumatic brain injury, treatment resistant major depressive disorder, disinhibition syndrome in patients with neurodegenerative disorders and neuropathic pain.
Otsuka Pharmaceutical overview
Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. It’s nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.
For a complete picture of (Deudextromethorphan hydrobromide + quinidine sulfate)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
